October 20, 2026
Law360 Healthcare Authority looks at the Second Circuit's denial of a drugmaker's request for full review of expert testimony for plaintiffs in a case alleging Tylenol causes autism, the preliminary approval of a $400 million settlement between Sandoz and a coalition of states in generic drug price-fixing litigation, and other legal news from the past week.
October 19, 2026
Mylan can use deposition testimony from one current and one former executive in next year's price-fixing trial, a Connecticut federal judge ruled Friday, but state attorneys general can bring up the company "pulling the strings" in the witnesses' decision to testify after originally invoking the Fifth Amendment.
October 16, 2026
A Connecticut federal judge granted preliminary approval Friday to a $400 million settlement between a coalition of states, Sandoz Inc. and its subsidiary Fougera Pharmaceuticals Inc. over allegations of generic drug price-fixing and market allocation, setting aside $280 million as restitution.
October 09, 2026
Taro Pharmaceuticals USA asked a Connecticut federal judge to toss generic-drug price-fixing claims brought by a coalition of states on behalf of consumers that are duplicative of claims the consumers have already resolved through settlements in separate multidistrict litigation.
October 08, 2026
Ascend Laboratories, Mayne Pharma and Citron Pharma asked a Connecticut federal judge Thursday to sign off on a settlement with a coalition of states resolving claims the companies were involved in an illegal conspiracy to fix prices and suppress competition for generic drugs in the United States.
October 02, 2026
A coalition of 43 states and territories is seeking court approval of a $400 million settlement that would resolve allegations Sandoz Inc. and its subsidiary Fougera Pharmaceuticals Inc. participated in a widespread price-fixing and market allocation conspiracy that raised the prices of generic drugs in the U.S.
October 01, 2026
A Connecticut federal judge has dismissed a swath of claims against a former executive of Actavis and Taro in the generic drug price‑fixing litigation brought by state enforcers, holding that evidence was insufficient to prove he joined several alleged single‑drug conspiracies.
September 29, 2026
Lupin Pharmaceuticals has reached a settlement with multiple states to resolve allegations that it conspired with G&W Laboratories Inc. to raise prices of the tuberculosis drug Ethambutol during a supply shortage years ago, according to a minute order entered in Connecticut federal court on Monday.
September 14, 2026
A Connecticut federal judge has tossed most of the claims against a former Perrigo executive in sprawling generic-drug price-fixing litigation brought by state enforcers, holding there is insufficient evidence he entered into antitrust conspiracies related to more than a dozen dermatological drugs, but teeing up a handful of other claims for trial.
August 25, 2026
A Connecticut federal judge gave a former Taro Pharmaceuticals USA Inc. marketing executive a partial victory in generic drug price-fixing litigation, tossing several claims by state attorneys general but allowing others to proceed after finding that a jury could conclude he joined certain conspiracies.